Amplitude Ventures

Congruence Therapeutics is a biotechnology company focused on drug discovery for diseases associated with protein misfolding. By integrating computational and experimental approaches, the company develops novel small molecules aimed at treating rare diseases. Utilizing structural bioinformatics, computational chemistry, and machine learning, Congruence has established an in silico platform that facilitates the design and validation of pharmacological stabilizers. This innovative approach allows researchers to create targeted therapeutic options for conditions linked to protein misfolding, advancing the field of biotechnology and improving treatment outcomes for affected patients.

InVivo AI is a Montreal-based company founded in 2017 that specializes in using artificial intelligence to enhance pharmaceutical research and development. The company primarily focuses on preclinical toxicology, aiming to improve the efficiency and effectiveness of drug development processes. By leveraging advanced AI technologies, InVivo AI seeks to transform traditional methodologies in the pharmaceutical industry, ultimately contributing to faster and more reliable outcomes in drug safety assessments.

Thryv Therapeutics is a biopharmaceutical company focused on developing therapies for long QT syndrome, a genetic disorder characterized by prolonged ventricular repolarization, which can lead to life-threatening arrhythmias. The company's research centers on SGK-1, a regulator of sodium channels in heart cells, which is implicated in the overactivity associated with long QT syndrome. By targeting this kinase, Thryv aims to address the underlying causes of the disorder and improve treatment options for affected patients. Based in Laval, Canada, the company is committed to advancing its pipeline to enhance patient outcomes in this critical area of cardiovascular health.

Giiant Pharma is a preclinical-stage biotechnology company focused on developing innovative therapies for inflammatory bowel diseases (IBD). Utilizing its proprietary Precision Delivery technology platform, Giiant designs gut-restricted, tissue-specific small molecule drug therapeutics that target specific biological pathways in gastroenterology. The company's lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug, which aims to improve drug tolerability while enhancing therapeutic effects. By releasing its active form specifically in the colon, Giiant's approach allows for targeted treatment at the site of inflammation, potentially preventing the worsening of patients' conditions.

Clementia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Montreal, Canada, focused on developing innovative treatments for patients with ultra-rare bone disorders and other diseases characterized by high unmet medical needs. Founded in 2010, the company specializes in disease-modifying therapies, with its lead product candidate being palovarotene, an oral small molecule. Palovarotene has demonstrated significant potential in preventing abnormal bone formation and fibrosis across various tissues. The candidate is currently undergoing evaluation in the Phase III MOVE trial, targeting conditions such as fibrodysplasia ossificans progressive and multiple osteochondromas, as well as dry eye disease. Clementia's commitment to addressing debilitating health issues highlights its role in advancing treatment options for affected patients.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on the development and commercialization of etripamil, a novel calcium channel blocker targeting various cardiovascular conditions. Etripamil is designed as a rapid-onset nasal spray for the self-administration by patients, specifically to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently advancing etripamil through Phase III clinical trials for PSVT in the United States and Canada, as well as conducting Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003, Milestone aims to address unmet medical needs in the treatment of transient cardiovascular conditions, including atrial fibrillation and angina.

Imagia Cybernetics Inc. is a Montreal-based company that specializes in medical image analysis solutions aimed at cancer detection and management. The company focuses on early detection and quantification of cancer changes, which is crucial for improving patient outcomes. Imagia's Artificial Clinical Intelligence Platform delivers timely insights into primary tumors and metastasis, thereby personalizing the cancer care continuum for patients. Utilizing a unique approach called Deep Radiomics, which combines radiomics and deep learning, the platform analyzes routine clinical imaging data to identify robust biomarkers that can predict patient outcomes. By leveraging advancements in artificial intelligence and federated learning, Imagia enhances the capabilities of clinicians, enabling them to conduct predictive, diagnostic, and prescriptive analytics while maintaining data privacy.